title: L-carnitine replacement therapy in chronic valproate treatment.
abstract: Ten epileptic children with chronic valproic acid (VPA) treatment were given L-carnitine for 14 days. As compared to age and sex matched control subjects the carnitine status of the VPA treated children showed carnitine insufficiency prior to the carnitine administration with lower total and free carnitine in plasma and in urine. In response to the extra intake the plasma free and esterified carnitines increased 1.7-fold. The daily excreted amount of esterified carnitines increased 6.5-fold (1.55 +/- 0.23 vs 10.1 +/- 1.68 mumol/kg/day, means +/- SEM, p less than 0.005) showing that a considerable part of the administered carnitine participated in the elimination of acyl groups from the body. The depressed level of beta-hydroxybutyrate in the plasma (31.8 +/- 7.42 vs controls 118.0 +/- 16.0 mumol/l, means +/- SEM, p less than 0.005) remained unaffected by the carnitine administration (29.7 +/- 7.06 mumol/l) suggesting that the hypoketonemia is not a direct consequence of the carnitine insufficiency. No differences were observed in the plasma level of free fatty acids, triglycerides and in insulin: glucagon ratios between the VPA treated and control subjects, suggesting that lipolysis of fats and the hepatic hormonal control mediated by these hormones are not the sites at which VPA causes reduced fasting ketogenesis. The plasma level of VPA and the seizure control remained unaffected by carnitine treatment.
authors.affiliation: Department of Pediatrics, University Medical School of Pécs, Hungary.
authors.forename: B
authors.initials: B
authors.lastname: Melegh
authors.forename: J
authors.initials: J
authors.lastname: Kerner
authors.forename: G
authors.initials: G
authors.lastname: Acsádi
authors.forename: J
authors.initials: J
authors.lastname: Lakatos
authors.forename: A
authors.initials: A
authors.lastname: Sándor
mesh_terms: D000293:Adolescent; D002331:Carnitine / Q000097:blood / Q000378:metabolism* / Q000652:urine; D002648:Child; D002908:Chronic Disease; D004827:Epilepsy / Q000188:drug therapy / Q000378:metabolism; D005260:Female; D006801:Humans; D007657:Ketone Bodies / Q000096:biosynthesis; D050356:Lipid Metabolism; D008297:Male; D014635:Valproic Acid / Q000009:adverse effects* / Q000097:blood / Q000627:therapeutic use
chemical_list: D007657:Ketone Bodies; D014635:Valproic Acid; D002331:Carnitine